Human Brain Cell DBTRG-05MG based Proliferation Assay Service
Our service provides the definitive, high-quality data required for fast and reliable go/no-go decisions in your glioblastoma (GBM) pipeline. At Creative Biolabs, we directly address the core challenge of GBM drug development: finding compounds that effectively halt the aggressive proliferation of the stem cell-like tumor phenotype. Our validated assays focus on the most therapeutically relevant GBM models, ensuring your candidates are tested against the actual cellular mechanisms driving tumor recurrence and resistance, thereby significantly de-risking your therapeutic program.
Background What We Can Offer Workflow Publication Why Choose Us FAQs Customer Review Related Services Contact Us
The Glioblastoma Challenge: Why Standard Screening Falls Short
GBM remains one of the most devastating and difficult-to-treat human malignancies. Its highly invasive nature, combined with the protective barrier of the central nervous system, necessitates novel therapeutic agents and, critically, screening models that accurately reflect the disease's aggressive phenotype. Standard proliferation assays often fail to capture the complexity and growth characteristics of relevant brain tumor cells, leading to false positives and delayed research pipelines. The DBTRG-05MG proliferation assay is centered on a gold-standard human glioblastoma multiforme cell line. This model is critical for testing novel anti-GBM agents against an aggressive, stem cell-like phenotype.
Specific Deliverables and Solutions for Lead Prioritization
Definitive IC50 Values
We deliver precise half-maximal inhibitory concentration data, the absolute prerequisite for prioritizing lead compounds and establishing appropriate dosing for in vivo studies.
Translational Relevance
By using the validated DBTRG-05MG human GBM tumor line, we ensure your compounds are tested against a highly relevant target, minimizing false positives.
Mechanistic Blueprint
Proliferation data serve as the foundation for complex follow-up studies, allowing seamless integration into downstream cell cycle, apoptosis, and signaling pathway analyses for full mechanistic characterization.
Discover How We Can Help - Request a Consultation
Workflow: Precision Screening from Compound to Conclusion
Creative Biolabs follows a systematic, quality-controlled workflow to ensure robust and reproducible data generation, which is crucial for regulatory submissions and publication.
Publication
This study identifies ubiquitin-specific protease 5 (USP5) as a critical promoter of GBM proliferation. Upregulated in GBM, USP5 stabilizes the cell cycle regulator CyclinD1 by removing its polyubiquitin chains, thus preventing proteasomal degradation. This stabilization drives the G1/S phase transition. Both in vitro and in vivo experiments confirmed that USP5 knockdown suppresses tumor growth, establishing USP5 as a key oncoprotein and promising therapeutic target for GBM.
Fig.1 USP5 promotes glioblastoma cell proliferation. 1
Why Choose Us
Creative Biolabs utilizes the DBTRG-05MG model because it is the definitive foundation for advanced glioblastoma research, backed by continuous scientific validation and confirmed by published data.
Molecular Pathway Confirmation
We confirm that target inhibition is linked to fundamental cell cycle pathways, validating the mechanism of action using the DBTRG-05MG model.
Benchmarking Against the Standard of Care
Our assays directly benchmark novel compounds against the current clinical standard, temozolomide (TMZ), providing crucial comparative efficacy data.
Advanced Drug Delivery Systems Validation
The DBTRG model is a key screening tool for validating nanoparticle-mediated delivery systems and other advanced drug carriers to overcome the blood-brain barrier.
Superior Luminescence Assay
Our ATP based luminescence readout provides a wider dynamic range and significantly higher sensitivity than traditional assays, minimizing noise and maximizing data integrity.
Experience the Creative Biolabs Advantage - Get a Quote Today
FAQs
Q1: What is the benefit of the luminescence based assay compared to a colorimetric MTT assay?
A1: Our luminescence assay detects ATP, a direct measure of metabolic activity in viable cells, offering superior sensitivity and a much wider dynamic range. Crucially, it eliminates potential interference caused by test compounds that might react with the colorimetric reagents used in MTT assays.
Q2: Can this service be used to screen drug combinations, not just single agents?
A2: Absolutely. Our high-throughput 96-well and 384-well formats are perfectly suited for combination screening, allowing for the rapid generation of synergy plots and IC50 shift data to identify optimal drug pairings that overcome resistance.
Q3: How do you ensure the cell line is authentic and relevant to my specific research goals?
A3: Creative Biolabs rigorously authenticates the DBTRG-05MG line before every campaign. Furthermore, our experts consult with you to select the appropriate positive and negative controls to ensure the assay is biologically relevant to your compound's mechanism of action.
Customer Review
-
High-Quality IC50 Data
Using Creative Biolabs' assay in our research has significantly improved the confidence in our compound prioritization, especially when compared directly to TMZ. The low variability in their data saved us months of re-screening. - J*hn D**s
-
Mechanistic Validation Simplified
The precision of their proliferation assay provided the necessary IC50 to justify our expensive follow-up G2/M cell cycle analysis. It facilitated rapid confirmation of our compound's ability to induce apoptosis in this aggressive cell line. - M*ry J*e
Related Services
To achieve comprehensive preclinical data, customers often pair the DBTRG-05MG proliferation assay with these complementary Creative Biolabs services:
Tumor Cell Panel Screening Service
Creative Biolabs' tumor cell panel screening service offers a diverse selection of cancer cell lines. This curated panel mirrors human tumor heterogeneity, providing an invaluable resource for screening anticancer compounds and investigating cancer mechanisms.
Learn More →
Biosafety Testing Service
Creative Biolabs offers comprehensive, off-the-shelf biologics safety and contamination testing to meet stringent regulatory requirements. Conducted in our biosafety laboratory, we ensure cell banks and clinical batches are sterile and free of contaminants.
Learn More →
Contact Us
Creative Biolabs is dedicated to advancing neuro-oncology research. Our human brain cell DBTRG-05MG based proliferation assay service provides the critical efficacy and mechanistic data required to fast-track your lead compounds from the bench to the bedside. By combining a phenotypically relevant GBM model with highly sensitive assay technology, we deliver results that are accurate, reliable, and translationally meaningful.
Contact Our Team for More Information and to Discuss Your Project
Reference
-
Li, Gen, et al. "USP5 Sustains the Proliferation of Glioblastoma Through Stabilization of CyclinD1." Frontiers in Pharmacology 12 (2021). Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fphar.2021.720307
